SSY Group Limited (HK:2005)
:2005
Want to see HK:2005 full AI Analyst Report?
2005 Stock Chart & Stats
HK$2.93
HK$0.03(0.93%)
At close: 4:00 PM EST
HK$2.93
HK$0.03(0.93%)
Day’s Range― - ―
52-Week RangeHK$2.24 - HK$3.40
Previous CloseN/A
Volume3.59M
Average Volume (3M)5.65M
Market Cap
HK$6.67B
Enterprise ValueHK$9.12B
Total Cash (Recent Filing)HK$1.82B
Total Debt (Recent Filing)HK$4.01B
Price to Earnings (P/E)14.0
Beta0.69
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.93%
Share Statistics
EPS (TTM)0.16
Shares Outstanding2,951,113,300
10 Day Avg. Volume4,536,404
30 Day Avg. Volume5,652,093
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.14
Price to Sales (P/S)1.99
P/FCF Ratio27.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.76Price Target Upside28.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.2
Revenue Forecast (FY)HK$4.88B
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthA moderate debt profile and steady asset growth provide financial flexibility and lower refinancing risk. This supports continued investment, M&A optionality, and the ability to withstand cyclical pressures, preserving strategic options over the next several quarters.
Free Cash Flow ReboundA material FCF recovery and consistently positive operating cash flow improve internal funding capacity for R&D, capex and dividends. Stronger cash conversion in 2025 enhances near-term liquidity and reduces dependence on external financing for strategic initiatives.
Historic Margin PerformanceA track record of high margins indicates durable competitive advantages—pricing power, scale or manufacturing efficiency. Even with a 2025 reset, historical margin strength suggests the company can restore profitability through cost actions or portfolio reprioritization.
Bears Say
2025 Revenue And Margin HitA meaningful top-line decline and margin compression reduce earnings power and cash flow sustainably if persistent. This pressures reinvestment, dividend coverage and strategic spending, and may require execution on new products or cost restructuring to reverse.
ROE DeteriorationA sharp fall in ROE signals weaker returns on shareholder capital and suggests current earnings are inadequate relative to equity. Persistently low ROE can constrain capital allocation choices and diminish long-term shareholder value creation.
Inconsistent Cash ConversionVariable cash conversion implies working-capital swings or lumpy investments, reducing predictability of free cash available for growth or distributions. This increases execution risk and complicates budgeting and long-term planning over the next several quarters.
SSY Group News
2005 FAQ
What was SSY Group Limited’s price range in the past 12 months?
SSY Group Limited lowest stock price was HK$2.24 and its highest was HK$3.40 in the past 12 months.
What is SSY Group Limited’s market cap?
SSY Group Limited’s market cap is HK$6.67B.
When is SSY Group Limited’s upcoming earnings report date?
SSY Group Limited’s upcoming earnings report date is Aug 31, 2026 which is in 77 days.
How were SSY Group Limited’s earnings last quarter?
SSY Group Limited released its earnings results on Mar 27, 2026. The company reported HK$0.063 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.063.
Is SSY Group Limited overvalued?
According to Wall Street analysts SSY Group Limited’s price is currently Undervalued.
Does SSY Group Limited pay dividends?
SSY Group Limited pays a Quarterly dividend of HK$0.03 which represents an annual dividend yield of 4.93%. See more information on SSY Group Limited dividends here
What is SSY Group Limited’s EPS estimate?
SSY Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SSY Group Limited have?
SSY Group Limited has 2,951,113,300 shares outstanding.
What happened to SSY Group Limited’s price movement after its last earnings report?
SSY Group Limited reported an EPS of HK$0.063 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.424%.
Which hedge fund is a major shareholder of SSY Group Limited?
Currently, no hedge funds are holding shares in HK:2005
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SSY Group Limited
SSY Group Limited operates as an investment holding entity primarily engaged in the pharmaceutical sector. The company's core operations encompass the research, development, production, and distribution of a diverse array of pharmaceutical goods, supplied to hospitals and distributors across the People's Republic of China and international markets. Its extensive product portfolio features various intravenous (IV) infusion solutions, such as non-PVC soft bags, upright soft bags, plastic and glass bottles, and ampoule injections. Additionally, SSY Group manufactures small volume injectable drugs, oral medications, traditional Chinese medicine formulations, biological preparations, bulk pharmaceutical ingredients, and medical supplies. Beyond its pharmaceutical manufacturing, the group is also involved in pharmaceutical technology research, development, and advisory services, as well as logistics for healthcare products. Intriguingly, the company also maintains operations in the food, beverage, and catering industries. Many of its offerings are marketed under the 'Shimen' brand. Founded in 2004, SSY Group Limited maintains its corporate headquarters in Wanchai, Hong Kong. The company underwent a name change from Lijun International Pharmaceutical (Holding) Co., Ltd. to its current designation in May 2015. Ultimately, SSY Group functions as a subsidiary of China Pharmaceutical Co., Ltd.
2005 Stock 12 Month Forecast
Average Price Target
HK$3.76
▲(28.33% Upside)
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Wai Yuen Tong Medicine Holdings Limited
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―
China Shineway Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---